epilepsy treatment New Seizure Drug Cuts Epilepsy Attacks by 91% in Children - New drug reduces seizures by 91% in children with rare, treatment-resistant epilepsy, offering breakthrough hope for families with limited treatment options.
cancer treatment New Cancer Drug Halves Disease Progression in Rare Tumor Patients New drug bezuclastinib reduces rare cancer progression risk by 50% in clinical trials, offering hope to GIST patients with limited treatment options.
medical breakthrough Thyroid Eye Disease Treatment Shows Major Clinical Success Phase 3 trial shows elegrobart significantly improves thyroid eye disease symptoms, offering new hope for patients with this disfiguring condition.
Health & Medicine FDA Approves Voyxact for Kidney Disease After Positive Trial First new treatment option offers hope for millions with IgA nephropathy
epilepsy New Epilepsy Drug Reduces Seizures by Up to 91% in Children with Rare Condition Medical breakthrough offers unprecedented hope for families battling devastating genetic condition
Health & Medicine Hearing Revolution: First Fully Implanted Cochlear Device Nears Approval Envoy Medical completes enrollment for first fully implanted cochlear implant, potentially eliminating external hardware for hearing loss treatment.
Cell Therapy Advanced Cell Therapy Shows Sustained Vision Improvements — March 7, 2026 RG6501 treatment maintains visual gains 36 months after transplantation
Cell Therapy Advanced Cell Therapy Shows Sustained Vision Improvements Advanced cell therapy RG6501 shows sustained vision improvements 36 months after treatment, offering hope for retinal disease patients through regenerative medicine.
Health & Medicine Psilocybin Therapy Clears Second Phase 3 Trial for Treatment-Resistant Depression Compass Pathways' COMP360 psilocybin therapy hits its primary endpoint in a second Phase 3 trial, bringing psychedelic-assisted psychiatry closer to regulatory approval.
Health & Medicine The 60-Year Wait May Be Ending: Two Non-Hormonal Male Contraceptives Enter Phase II Trials Two non-hormonal male contraceptives — a long-acting injectable and an on-demand pill — enter Phase II clinical trials.
